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Abstract
Medicines constitute a substantial proportion of out-of-pocket (OOP) expenses in Indian households. In order to 
address this issue, the Government of India launched the Jan Aushadhi (Medicine for the Masses) Scheme (JAS) 
to provide cheap generic medicines to the patients (http://janaushadhi.gov.in/about_jan_aushadhi.html). These 
medicines are provided through the Jan Aushadhi stores established across the country. The objective of this study was 
to do a quick assessment for policy-makers regarding the objective of the JAS.  Implications on cost savings for patients 
and policy implications of the scheme were analyzed. Secondary data sources were used to obtain prices of medicines 
under the JAS and prices of branded medicines of the same formulations. A cost analysis design was used. There are 
substantial differences between the JAS price and the cheapest branded medicine available in the market. However, 
not all JAS prices are lower than branded medicines. For example, the cheapest branded cefuroxime axetil (500 mg) 
(antibiotic) in the market is almost three times cheaper than its JAS price. Hence, there are cheaper brands available for 
some commonly prescribed medicines. From the policy perspective, it raises serious questions regarding the pricing of 
medicines in the JAS and its overarching goal. Since patients are dependent on physicians for medicine prescriptions 
and have little knowledge of the price variations among branded and generic medicines, the JAS may not provide the 
cheapest alternative for the patients. Hence, the government should urgently review the JAS prices to achieve its goal 
of providing low-cost affordable medicines.
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Background 
The trend of using medications to treat diseases has been 
increasing worldwide since the acceptance of modern 
medicine as a scientific and reliable mode of treatment. Drugs 
and medicines form a substantial portion of out-of-pocket 
(OOP) spending on health among households in India and 
have become a major source of catastrophic expenditure for 
both outpatient services as well as inpatient (hospitalization) 
charges.1 Private OOP expenditure by the low income 
households on medicines is responsible for pushing families 
into poverty. 
The extent of OOP expenditure is so high that some 
affected patients and households have to take loans to buy 
medicines. This meant that the expenditure on medicines was 
responsible for pushing the rural and urban poor into debt. 
A study over a period of four weeks showed that 41%-56% 
of households surveyed in low- and middle-income countries 
had solely spent their health expenses on medicines.2 Another 
study from three north Indian states on burden of medicines 
showed that the reason for debt was medical expenditure in 
25% of the urban households and 19% of rural households,3 
which suggested that the poor were approaching lenders for 
borrowing money or selling their assets in order to meet 
the healthcare expenses. In India, most patients who seek 
treatment for acute and chronic diseases face a major crisis for 
accessing essential medicines.4 In such situations, it is critical 
to have alternatives to decrease the OOP expenditure due to 
medicines.
An ideal solution would be free distribution of medicines; 
but its financial feasibility for the union government is very 
poor in India. The Indian government spends just over 1% 
of the gross domestic product (GDP) on healthcare and 
repeated union budgets have shown that its nearly impossible 
to improve the funding to healthcare. Also, neoliberal policies 
favoring market mechanisms with decreased role of the state 
in healthcare are being envisaged. Hence, another alternative 
would be to involve the private sector to decrease the costs of 
the medicines or distribute them freely, which is impossible 
due to the profit motivations of this sector. In a situation 
where the government would not spend more on healthcare 
and the patient cannot avoid private healthcare services, 
an important alternative to decrease the patients’ OOP 
expenditure is through the use of generic medicines. Generic 
medicines are usually cheaper than branded medicines and 
are useful in decreasing the expenditure on medicines.2 
Mass production of generic anti-retroviral medicines saved 
the lives of millions of HIV/AIDS patients by making the 
medicines more accessible and affordable in the low- and 
middle-income countries.5 Countries that intended to curtail 
their expenses and save the citizens from OOP expenditure 
on medicines adopted policies in favour of generic medicine.6
To make generic medicines available to the population, 
the Department of Pharmaceuticals, Government of India 
launched the Jan Aushadhi Scheme (JAS) (medicine for the 
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masses) in 2008. Under the scheme, Jan Aushadhi generic drug 
stores were opened across the country to provide low-cost 
generic medicines to the population. However, many of these 
stores are currently non-functional or have closed for various 
reasons like poor support from state governments, poor supply 
chain management, non-prescription of generic medicines by 
the doctors, lack of awareness, etc. Recognizing the weakness 
in the scheme’s implementation, the government is planning 
to re-launch its pharmacy chain, Jan Aushadhi stores, to sell 
generic medicines ranging from antibiotics, anti-cardiac, 
anti-infective and gastrointestinal medicines at least half the 
price of branded medicines. While the implementation of 
this relaunch is pending, this paper analyses a fundamental 
premise of this scheme ie, generic medicines given through 
JAS will be cheaper than branded medicines available in the 
market. A comparative cost analysis of generic medicines 
available under JAS with branded medicines of the same 
formulation available in the market was performed.
Methods
A cost analysis was performed in this study. This study 
considers the price of the medicine as the direct cost to 
patients. Various studies have proven that the efficacy and 
effectiveness of generic medicines is the same as branded 
medicines.7,8 Hence, the price of medicines listed in JAS was 
compared with the price of the same branded formulation 
sold in the market. Also, the study assumes that the direct 
non-medical costs like transportation costs to avail these 
medicines would be the same for patients accessing either 
the Jan Aushadhi stores or the private chemists who sell the 
branded medicines. The sources of cost data include the JAS 
website and MedGuideIndia.com. Three medicines were 
selected for comparison. The selection of the three drugs was 
based on issues of immediate concern expressed by policy-
makers and included the following:
1.	 Medicine of choice for addressing risk factor (cholesterol) 
for non-communicable disease (NCD): atorvastatin.
2.	 Commonly prescribed antibiotic in India for serious 
infectious diseases: cefuroxime axetil.
3.	 Medicine of choice for anxiety in India: alprazolam.
Limitations
Since, the study restricts itself to analyzing the direct cost of 
medicines, no conclusions can be made on the effect on the 
indirect costs associated with any of these medicines. This 
study examined only three medications, as the objective was 
a quick assessment of the objectives of JAS. A detailed study 
with a larger sample of drugs would give more insights along 
with analysis of utilization information.
Results
The JAS medicines cover a wide range of communicable 
diseases, NCDs (cardiovascular diseases, diabetes), mental 
disorders like anxiety, analgesics, vitamin, iron, folic acid 
supplements, and tetanus toxoid injections.9 As shown in Table 
1, there is a huge variation in the prices of atorvastatin in the 
branded market. Also, the price of the branded atorvastatin is 
2 to 25 times more than the JAS price. Hence, a patient taking 
statins from the Jan Aushadhi generic drug stores would save 
substantially. However, as shown in Table 2, in the case of 
the antibiotic cefuroxime axetil, there are cheaper varieties 
available in the branded market than the JAS price. However, 
the price of alprazolam in the JAS is the among the lowest as 
compared to market prices (Table 3).
There are 256 brands of atorvastatin (10 mg) available in the 
Indian market and the mean branded price of atorvastatin 
(10 mg) is INR 57.58 (standard deviation [SD] = 17.90). 
The difference between JAS price and mean branded price 
of atorvastatin (10 mg) is INR 52.82. There are 173 brands 
of atorvastatins (20 mg) available with a mean cost of INR 
106.00 (SD = 36.71). The difference between the JAS price and 
mean branded price of atorvastatin (20 mg) is INR 97.44.
The mean branded price of the 192 available brands of 
cefuroxime axetil (250 mg) is INR 249.27 (SD = 73.54). The 
difference between the JAS price and mean branded price 
of cefuroxime axetil (250 mg ) is INR -182.90. The mean 
branded price of 180 available brands of cefuroxime axetil 
(500) is INR 447.23 (SD = 146.09). The difference between the 
JAS price and mean branded price of cefuroxime axetil (500 
mg) is INR -318.37.
The mean branded price of 229 brands of alprazolam (0.25 
mg ) is INR 9.35 (SD = 3.09). The difference between JAS price 
and mean branded price of alprazolam (0.25 mg) is INR 7.51.
The mean branded price of the 244 available brands of 
alprazolam (0.50 mg) is INR 17.20 (SD = 5.61). The difference 
between JAS price and mean branded price of alprazolam 
(0.50 mg) is INR 14.23.
Table 1. Cost Comparison of Atorvastatin
 Statins  Package Unit JAS Price (INR)
Branded Price (INR) % Difference With JAS Price
Lowest Highest Lowest Highest
Atorvastatin (10 mg) 10 tabs 4.76 12 118.5 152 2389
Atorvastatin (20 mg) 10 tabs 8.56 19 212.38 122 2381
Abbreviations: INR, Indian Rupees; JAS, Jan Aushadhi Scheme.
Table 2. Cost Comparison of Cefuroxime Axetil
 Antibiotic  Package Unit JAS Price (INR)
Branded Price (INR) % Difference With JAS Price
Lowest Highest Lowest Highest
Cefuroxime axetil (250 mg) 10 tabs 66.37 26 500 -60 653
Cefuroxime Aaxetil (500 mg) 10 tabs 128.86 43 780 -66 505
Abbreviations: INR, Indian Rupees; JAS, Jan Aushadhi Scheme.
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Discussion
Medicines play a major role in protecting, maintaining 
and restoring people’s health. The provision of appropriate 
medicines of assured quality, in adequate quantities and 
at reasonable prices is, therefore, a concern of global and 
national policy-makers and agencies implementing health 
activities and programs.10 Drugs and medicines form a 
substantial portion of OOP spending on health among 
households in India.11 In the context of providing universal 
healthcare, providing financial risk protection to households 
affected by illness is a key objective with focus on providing 
cover for medicines.12 In fact, improving access to essential 
medicines in India is a public health and ethical imperative.4
Since medicines constitute the majority of OOP expenses in 
India, making cheap generic medicines available for patient 
households would be an important strategy to achieve the 
objective. In Europe, generic medicines reduced the region’s 
medicine bill by 61% in 2014.13 Even in developing countries, 
substantial savings could be achieved by switching private 
sector purchases from branded medicines to lowest-priced 
generic equivalents.14
The JAS is a policy initiative in that direction. The recent 
union budget of India in 2016 announced an impetus to this 
scheme.15 However, as the study shows, the price of some 
generic medicines available under JAS is costlier than the 
corresponding branded medicine available in the market. 
Furthermore, these are routinely prescribed medicines for 
common health conditions in the general population. This 
suggests that the existing pricing of JAS would actually 
increase the OOP expenditure of patient households, which 
fails the purpose and objective of the scheme. From the 
policy perspective, it raises serious questions regarding the 
pricing of medicines in JAS and the goal to be achieved. 
From the public perspective, JAS is an important initiative 
of the Government of India and targets a wide range of 
medical conditions commonly seen in the population. In 
India, patients depend heavily on doctors for medicine 
prescriptions and prescription practices are very poorly 
regulated. The unethical promotional practices adopted by 
the pharmaceutical companies make essential medicines 
unaffordable to the common man.16 Also, patients have poor 
or no knowledge of the price variations among branded and 
generic medicines, and leave the choice of the medicine to 
the doctor. Hence, even if there is a regulation for doctors 
to prescribe only generic medicines from the JAS, it may 
still not be the cheapest alternative available and would still 
create a large OOP expenditure on medicines by households. 
No independent studies have compared the price difference 
between JAS price and market price of medicine. The only 
study done on the JAS addressed the issue of quality of generic 
medicines in the JAS and found that the medicines tested after 
procuring from Jan Aushadhi sources are of equivalent and 
comparable quality to their counterpart branded medicines 
available in the market.17 Hence, it is not quality but cost of 
medicines in JAS which may make the scheme a failure. 
Conclusion
The study shows that while the JAS price is among the lowest 
in the market for medicines like alprazolam and atorvastatin, 
there are cheaper branded medicines available in the market 
for a commonly prescribed antibiotic (cefuroxime axetil). 
From the policy perspective, it raises serious questions 
regarding the pricing of medicines in JAS and the goal to 
be achieved. With information asymmetry and supplier 
induced demand feature in the healthcare market, the OOP 
expenditure due to medicines is unlikely to decline in India 
with the existing JAS. Hence, it is strongly recommended that 
the Government of India reviews the medicine pricing policy 
under the JAS. In addition, strong supply side regulation, 
such as prescription audits, are necessary to prevent the 
widespread prescription of costly branded medicines. If this is 
not done, the JAS policy will not be able to meet its objective 
of providing low-cost affordable medicine and financial risk 
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